07:13 AM EDT, 07/15/2025 (MT Newswires) -- Rakovina Therapeutics (RKV.V), a biopharmaceutical company, on Tuesday said its shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC).

"Achieving DTC eligibility is a meaningful step forward in increasing Rakovina's visibility and accessibility to a broader base of institutional and retail investors," said Rakovina Therapeutics Executive Chairman Jeffrey Bacha. "It removes a key barrier to efficient trading in the U.S., enhances liquidity, and establishes the foundation for deeper engagement with U.S. capital markets as we continue to execute our growth strategy."

Shares of the company closed up 1.5% to $0.70 on Monday on the TSX Venture Exchange.